The European Palliative Care Cancer Symptom Study (EPCCS) (EPCCS)

Tracking Information
First Submitted Date	May 27, 2011
First Posted Date	May 30, 2011
Last Update Posted Date	August 2, 2016
Study Start Date	June 2011
Actual Primary Completion Date	October 2013 (Final data collection date for primary outcome measure)
Current Primary Outcome Measures; (submitted: January 9, 2013)	change in cancer symptoms [ Time Frame: up to 6 months ]; assessment and classification system developed by the European Palliative Care Research Collaborative (EPCRC) / European Association for Palliative Care Research Network (EAPC RN)
Original Primary Outcome Measures	Not Provided
Change History	Complete list of historical versions of study NCT01362816 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures	Not Provided
Original Secondary Outcome Measures	Not Provided
Current Other Outcome Measures	Not Provided
Original Other Outcome Measures	Not Provided
Descriptive Information
Brief Title	The European Palliative Care Cancer Symptom Study (EPCCS)
Official Title	The European Palliative Care Cancer Symptom Study (EPCCS). A Prospective Data Collection
Brief Summary	The rising incidence of cancer and the rapidly increasing number of people living longer with incurable disease, accentuates the need for optimal symptom management throughout the disease trajectory. Thanks to the medical and technological development, and the increased interest in palliative care research, palliative medicine has gradually become more evidence based. Patients with advanced cancer experience multiple symptoms at the time with fluctuating intensity and severity. Pain, fatigue, nausea/vomiting, dyspnea, loss of appetite and depression are among the most common and experienced by more than 50%. However, the prevalence rates of these symptoms vary considerably across studies, with a range from 35 to 90 % for pain as an example. These differences may in part be explained by different assessment tools, study methods and design and population characteristics. There is also lack of agreed-upon, common criteria to describe the main characteristics of a palliative care cancer population and few standardized tools for assessment and classification of symptoms exist. These shortcomings limit the possibility to design randomized controlled treatment trials in palliative care; the optimal way to improve clinical symptom management. To do this, a better understanding of how symptoms evolve and how they should be assessed and classified throughout the palliative care disease trajectory is important, supplemented with registrations of the treatment provided. The primary aim of this international research project the European Palliative Care Cancer Symptom study (EPCCS) is to extend the knowledge about and gain new insight in the prevalence and development of the most frequent cancer related symptoms during the course of disease, in a large sample of palliative care cancer patients. The clinical usefulness of the new assessment and classification system developed by the European Palliative Care Research Collaborative (EPCRC) / European Association for Palliative Care Research Network (EAPC RN) will be examined and data on the organization and delivery of palliative care at participating centers will be collected. The project also aims to further develop and consolidate international research collaboration through the European Palliative Care Research Centre (PRC). Taken together, these efforts will increase the understanding of the palliative disease trajectory and provide necessary knowledge and structure for future randomized controlled trials (RCTs)
Detailed Description	Not Provided
Study Type	Observational
Study Design	Observational Model: Cohort; Time Perspective: Prospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Non-Probability Sample
Study Population	The popuation consists of patients with incurable cancers who are enrolled in a palliative care programme. They will be identified upon referral for non-curative cancer treatment/palliative care to the centre, department, out-patient clinic, daycare centre, hospice, or home-based care, depending on the palliaitve care organization model at the participating centres. Patients will be followed every 4 weeks (3-5) for at least 6 months, or until death
Condition	Cancer
Intervention	Not Provided
Study Groups/Cohorts	Palliative care cancer patients; Inclusion criteria are: Patient has a cancer diagnosis (radiological, histological, cytological or operative evidence), local, loco-regional or metastatic disease, defined as a palliative care patient; enrolled in a palliative care programme, age 18 years or older, able to provide written informed consent, able to complete the data collection tool, preferably without help, available for follow up registration
Publications *	Ekström M, Johnson MJ, Schiöler L, Kaasa S, Hjermstad MJ, Currow DC. Who experiences higher and increasing breathlessness in advanced cancer? The longitudinal EPCCS Study. Support Care Cancer. 2016 Sep;24(9):3803-11. doi: 10.1007/s00520-016-3207-1. Epub 2016 Apr 9.; Habberstad R, Hjermstad MJ, Brunelli C, Kaasa S, Bennett MI, Pardon K, Klepstad P. Which factors can aid clinicians to identify a risk of pain during the following month in patients with bone metastases? A longitudinal analyses. Support Care Cancer. 2018 Aug 13. doi: 10.1007/s00520-018-4405-9. [Epub ahead of print]; Hjermstad MJ, Aass N, Aielli F, Bennett M, Brunelli C, Caraceni A, Cavanna L, Fassbender K, Feio M, Haugen DF, Jakobsen G, Laird B, Løhre ET, Martinez M, Nabal M, Noguera-Tejedor A, Pardon K, Pigni A, Piva L, Porta-Sales J, Rizzi F, Rondini E, Sjøgren P, Strasser F, Turriziani A, Kaasa S; European Palliative Care Cancer Symptom study (EPCCS). Characteristics of the case mix, organisation and delivery in cancer palliative care: a challenge for good-quality research. BMJ Support Palliat Care. 2016 May 31. pii: bmjspcare-2015-000997. doi: 10.1136/bmjspcare-2015-000997. [Epub ahead of print]
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status	Completed
Actual Enrollment; (submitted: August 25, 2015)	1739
Original Estimated Enrollment; (submitted: May 27, 2011)	1200
Actual Study Completion Date	October 2013
Actual Primary Completion Date	October 2013 (Final data collection date for primary outcome measure)
Eligibility Criteria	Inclusion Criteria: Patient has a cancer diagnosis (radiological, histological, cytological or operative evidence); Local, loco-regional or metastatic disease; Defined as a palliative care patient; enrolled in a palliative care programme; Age 18 years or older; Able to provide written informed consent; Able to complete the data collection tool, preferably without help; Available for follow up registration Exclusion Criteria: Patients receiving anti-cancer treatment with a curative intent; Patients who are unable to complete the registration due to language problems or severe physical problems; Patients who have psychotic disorders or obvious cognitive impairment; Patients who cannot come for regular follow-up visits, due to geographical or social reasons
Sex/Gender	Sexes Eligible for Study: All
Ages	18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers	No
Contacts	Contact information is only displayed when the study is recruiting subjects
Listed Location Countries	Norway
Removed Location Countries
Administrative Information
NCT Number	NCT01362816
Other Study ID Numbers	2010/2945-3
Has Data Monitoring Committee	No
U.S. FDA-regulated Product	Not Provided
IPD Sharing Statement	Not Provided
Responsible Party	Norwegian University of Science and Technology
Study Sponsor	Norwegian University of Science and Technology
Collaborators	Rigshospitalet, Denmark; Oslo University Hospital; Medical University of Graz; University of Navarra; Hospital Universitario La Paz; Cantonal Hospital of St. Gallen; Institut Català d'Oncologia; University of Alberta; Flinders University; University Hospital, Ghent; The Cleveland Clinic; Hospital de San Lázaro; Haukeland University Hospital; Kantonsspital Graubünden; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; University of Edinburgh; Leeds Cancer Centre at St. James; Turku University Hospital; St George's, University of London
Investigators	Principal Investigator: Stein Kaasa, Prof MD Norwegian University of Science and Technology Principal Investigator: Marianne J Hjermstad, PhD Norwegian University of Science and Technology
PRS Account	Norwegian University of Science and Technology
Verification Date	July 2016